Farcast has been a leader in translational and Tumor Microenvironment (TME) research since inception at MIT in 2012. With experience of evaluating 25,000+ human tissues across multiple mechanisms for immunotherapy, such as T-cell modulation, Myeloid reprogramming, Stromal modulation, Engineered immune cells and many others 

​​

Our human tumor models can rapidly generate rich data from tumor organoids and TME platform that accurately captures functional response that is biologically relevant in the context of human tumors. Our versatile AI/ML solutions can be used flexibly for your existing data sets and mapped to Farcast existing biosignatures for an enriched understanding of your data to increase confidence in response and resistance characteristics. We offer specialized expertise across all aspects of translational research in oncology.

​​

Farcast is ISO 9001 certified and is rapidly expanding its network beyond the existing set of 20 cancer centers